Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system (T48)
Clinical Information
Acetylcysteine - The N-acetyl derivative of CYSTEINE. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates.
Albuterol - A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
Albuterol, Ipratropium Drug Combination - A combined pharmaceutical preparation of Ipratropium Bromide and Albuterol Sulfate that is used to treat the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
Ambroxol - A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
Aminophylline - A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.
Bromhexine - A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744)
Carboprost - A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of PREGNANCY.
Choline - A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.
Choline Deficiency - A condition produced by a deficiency of CHOLINE in animals. Choline is known as a lipotropic agent because it has been shown to promote the transport of excess fat from the liver under certain conditions in laboratory animals. Combined deficiency of choline (included in the B vitamin complex) and all other methyl group donors causes liver cirrhosis in some animals. Unlike compounds normally considered as vitamins, choline does not serve as a cofactor in enzymatic reactions. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)
Choline Dehydrogenase - An enzyme bound to the inner mitochondrial membrane that catalyzes the oxidation of CHOLINE to BETAINE.
Choline Kinase - An enzyme that is active in the first step of choline phosphoglyceride (lecithin) biosynthesis by catalyzing the phosphorylation of choline to phosphorylcholine in the presence of ATP. Ethanolamine and its methyl and ethyl derivatives can also act as acceptors. EC 2.7.1.32.
Choline O-Acetyltransferase - An enzyme that catalyzes the formation of acetylcholine from acetyl-CoA and choline. EC 2.3.1.6.
Choline-Phosphate Cytidylyltransferase - An enzyme that catalyzes the transfer of cytidylate (CMP) to choline phosphate to form CDPcholine. It is the rate-limiting enzyme in the choline pathway for the biosynthesis of phosphatidylcholine. Its activity is increased by glucocorticoids. EC 2.7.7.15.
Cholinergic Agents - Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of ACETYLCHOLINE, and drugs that affect the survival of cholinergic neurons. The term cholinergic agents is sometimes still used in the narrower sense of MUSCARINIC AGONISTS, although most modern texts discourage that usage.
Cholinergic Agonists - Drugs that bind to and activate cholinergic receptors.
Cholinergic Antagonists - Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists.
Cholinergic Fibers - Nerve fibers liberating acetylcholine at the synapse after an impulse.
Cholinergic Neurons - Neurons whose primary neurotransmitter is ACETYLCHOLINE.
Cholinesterase Inhibitors - Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.
Cholinesterase Reactivators - Drugs used to reverse the inactivation of cholinesterase caused by organophosphates or sulfonates. They are an important component of therapy in agricultural, industrial, and military poisonings by organophosphates and sulfonates.
Cholinesterases - Drugs used to reverse the inactivation of cholinesterase caused by organophosphates or sulfonates. They are an important component of therapy in agricultural, industrial, and military poisonings by organophosphates and sulfonates.
Clenbuterol - A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
Cytidine Diphosphate Choline - Donor of choline in biosynthesis of choline-containing phosphoglycerides.
Cytochrome P-450 CYP2D6 - A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population.
Dextromethorphan - Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.
Diacylglycerol Cholinephosphotransferase - An enzyme that catalyzes the synthesis of phosphatidylcholines from CDPcholine and 1,2-diacylglycerols. EC 2.7.8.2.
Dinoprost - A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.
Dinoprostone - The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa.
Ergonovine - An ergot alkaloid (ERGOT ALKALOIDS) with uterine and VASCULAR SMOOTH MUSCLE contractile properties.
Expectorants - Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here.
Fenoterol - A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.
Glycerylphosphorylcholine - A component of PHOSPHATIDYLCHOLINES or LECITHINS, in which the two hydroxy groups of GLYCEROL are esterified with fatty acids. (From Stedman, 26th ed)
Glycyrrhizic Acid - A widely used anti-inflammatory agent isolated from the licorice root. It is metabolized to GLYCYRRHETINIC ACID, which inhibits 11-BETA-HYDROXYSTEROID DEHYDROGENASES and other enzymes involved in the metabolism of CORTICOSTEROIDS. Therefore, glycyrrhizic acid, which is the main and sweet component of licorice, has been investigated for its ability to cause hypermineralocorticoidism with sodium retention and potassium loss, edema, increased blood pressure, as well as depression of the renin-angiotensin-aldosterone system.
Guaifenesin - An expectorant that also has some muscle relaxing action. It is used in many cough preparations.
Hexoprenaline - Stimulant of adrenergic beta 2 receptors. It is used as a bronchodilator, antiasthmatic agent, and tocolytic agent.
Isoproterenol - Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
Leukemia Inhibitory Factor - An INTERLEUKIN-6 related cytokine that exhibits pleiotrophic effects on many physiological systems that involve cell proliferation, differentiation, and survival. Leukemia inhibitory factor binds to and acts through the lif receptor.
Levalbuterol - The R-isomer of albuterol.
Menthol - A monoterpene cyclohexanol produced from mint oils.
Metaproterenol - A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM.
Methylergonovine - A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed)
Muscarinic Agonists - Drugs that bind to and activate muscarinic cholinergic receptors (RECEPTORS, MUSCARINIC). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate.
Muscarinic Antagonists - Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
Naphazoline - An adrenergic vasoconstrictor agent used as a decongestant.
Nedocromil - A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with ASTHMA, including EOSINOPHILS; NEUTROPHILS; MACROPHAGES; MAST CELLS; MONOCYTES; AND PLATELETS.
Neuroimmunomodulation - The biochemical and electrophysiological interactions between the NERVOUS SYSTEM and IMMUNE SYSTEM.
Nicotinic Agonists - Drugs that bind to and activate nicotinic cholinergic receptors (RECEPTORS, NICOTINIC). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarizing blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission.
Non-Neuronal Cholinergic System - The system of ACETYLCHOLINE-synthesizing enzymes, transporters, receptors and degrading enzymes that characterize non-neuronal cholinergic cells such as airway and skin EPITHELIAL CELLS.
Noscapine - A naturally occurring opium alkaloid that is a centrally acting antitussive agent.
Oxymetazoline - A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)
Phosphatidylcholines - Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.
Phosphorylcholine - Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
Receptors, Cholinergic - Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology.
Solute Carrier Family 44, Member 2 Protein - A mitochondrion and plasma membrane protein that enables choline transmembrane transporter activity.
Sparteine - A quinolizidine alkaloid isolated from several FABACEAE including LUPINUS; SPARTIUM; and CYTISUS. It has been used as an oxytocic and an anti-arrhythmia agent. It has also been of interest as an indicator of CYP2D6 genotype.
Succinylcholine - A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.
Terbutaline - A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.
Theophylline - A methyl xanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Theophylline inhibits the 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE that degrades CYCLIC AMP thus potentiates the actions of agents that act through ADENYLYL CYCLASES and cyclic AMP.
Tretoquinol - An adrenergic beta-agonist used as a bronchodilator agent in asthma therapy.
Vecuronium Bromide - Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.
Instructional Notations
7th Character Note
Certain ICD-10-CM categories have applicable 7th characters. The applicable 7th character is required for all codes within the category, or as the notes in the Tabular List instruct. The 7th character must always be the 7th character in the data field. If a code that requires a 7th character is not 6 characters, a placeholder X must be used to fill in the empty characters.
- The appropriate 7th character is to be added to each code from category T48
7th Character
Indicates that a seventh character is to be assigned to codes in a subcategory.
- A - initial encounter
- D - subsequent encounter
- S - sequela
Injury, poisoning and certain other consequences of external causes (S00–T88)
Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances (T36-T50)
T48 Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system
T48.0 Poisoning by, adverse effect of and underdosing of oxytocic drugs
T48.0X Poisoning by, adverse effect of and underdosing of oxytocic drugs
T48.0X1 Poisoning by oxytocic drugs, accidental (unintentional)
- T48.0X1A Poisoning by oxytocic drugs, accidental (unintentional), initial encounter
- T48.0X1D Poisoning by oxytocic drugs, accidental (unintentional), subsequent encounter
- T48.0X1S Poisoning by oxytocic drugs, accidental (unintentional), sequela
T48.0X2 Poisoning by oxytocic drugs, intentional self-harm
- T48.0X2A Poisoning by oxytocic drugs, intentional self-harm, initial encounter
- T48.0X2D Poisoning by oxytocic drugs, intentional self-harm, subsequent encounter
- T48.0X2S Poisoning by oxytocic drugs, intentional self-harm, sequela
T48.0X3 Poisoning by oxytocic drugs, assault
- T48.0X3A Poisoning by oxytocic drugs, assault, initial encounter
- T48.0X3D Poisoning by oxytocic drugs, assault, subsequent encounter
- T48.0X3S Poisoning by oxytocic drugs, assault, sequela
T48.0X4 Poisoning by oxytocic drugs, undetermined
- T48.0X4A Poisoning by oxytocic drugs, undetermined, initial encounter
- T48.0X4D Poisoning by oxytocic drugs, undetermined, subsequent encounter
- T48.0X4S Poisoning by oxytocic drugs, undetermined, sequela
T48.0X5 Adverse effect of oxytocic drugs
- T48.0X5A Adverse effect of oxytocic drugs, initial encounter
- T48.0X5D Adverse effect of oxytocic drugs, subsequent encounter
- T48.0X5S Adverse effect of oxytocic drugs, sequela
T48.0X6 Underdosing of oxytocic drugs
- T48.0X6A Underdosing of oxytocic drugs, initial encounter
- T48.0X6D Underdosing of oxytocic drugs, subsequent encounter
- T48.0X6S Underdosing of oxytocic drugs, sequela
T48.1 Poisoning by, adverse effect of and underdosing of skeletal muscle relaxants [neuromuscular blocking agents]
T48.1X Poisoning by, adverse effect of and underdosing of skeletal muscle relaxants [neuromuscular blocking agents]
T48.1X1 Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], accidental (unintentional)
- T48.1X1A Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], accidental (unintentional), initial encounter
- T48.1X1D Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], accidental (unintentional), subsequent encounter
- T48.1X1S Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], accidental (unintentional), sequela
T48.1X2 Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm
- T48.1X2A Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, initial encounter
- T48.1X2D Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, subsequent encounter
- T48.1X2S Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, sequela
T48.1X3 Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], assault
- T48.1X3A Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], assault, initial encounter
- T48.1X3D Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], assault, subsequent encounter
- T48.1X3S Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], assault, sequela
T48.1X4 Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], undetermined
- T48.1X4A Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], undetermined, initial encounter
- T48.1X4D Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], undetermined, subsequent encounter
- T48.1X4S Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], undetermined, sequela
T48.1X5 Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents]
- T48.1X5A Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
- T48.1X5D Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], subsequent encounter
- T48.1X5S Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], sequela
T48.1X6 Underdosing of skeletal muscle relaxants [neuromuscular blocking agents]
- T48.1X6A Underdosing of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
- T48.1X6D Underdosing of skeletal muscle relaxants [neuromuscular blocking agents], subsequent encounter
- T48.1X6S Underdosing of skeletal muscle relaxants [neuromuscular blocking agents], sequela
T48.2 Poisoning by, adverse effect of and underdosing of other and unspecified drugs acting on muscles
T48.20 Poisoning by, adverse effect of and underdosing of unspecified drugs acting on muscles
T48.201 Poisoning by unspecified drugs acting on muscles, accidental (unintentional)
- T48.201A Poisoning by unspecified drugs acting on muscles, accidental (unintentional), initial encounter
- T48.201D Poisoning by unspecified drugs acting on muscles, accidental (unintentional), subsequent encounter
- T48.201S Poisoning by unspecified drugs acting on muscles, accidental (unintentional), sequela
T48.202 Poisoning by unspecified drugs acting on muscles, intentional self-harm
- T48.202A Poisoning by unspecified drugs acting on muscles, intentional self-harm, initial encounter
- T48.202D Poisoning by unspecified drugs acting on muscles, intentional self-harm, subsequent encounter
- T48.202S Poisoning by unspecified drugs acting on muscles, intentional self-harm, sequela
T48.203 Poisoning by unspecified drugs acting on muscles, assault
- T48.203A Poisoning by unspecified drugs acting on muscles, assault, initial encounter
- T48.203D Poisoning by unspecified drugs acting on muscles, assault, subsequent encounter
- T48.203S Poisoning by unspecified drugs acting on muscles, assault, sequela
T48.204 Poisoning by unspecified drugs acting on muscles, undetermined
- T48.204A Poisoning by unspecified drugs acting on muscles, undetermined, initial encounter
- T48.204D Poisoning by unspecified drugs acting on muscles, undetermined, subsequent encounter
- T48.204S Poisoning by unspecified drugs acting on muscles, undetermined, sequela
T48.205 Adverse effect of unspecified drugs acting on muscles
- T48.205A Adverse effect of unspecified drugs acting on muscles, initial encounter
- T48.205D Adverse effect of unspecified drugs acting on muscles, subsequent encounter
- T48.205S Adverse effect of unspecified drugs acting on muscles, sequela
T48.206 Underdosing of unspecified drugs acting on muscles
- T48.206A Underdosing of unspecified drugs acting on muscles, initial encounter
- T48.206D Underdosing of unspecified drugs acting on muscles, subsequent encounter
- T48.206S Underdosing of unspecified drugs acting on muscles, sequela
T48.29 Poisoning by, adverse effect of and underdosing of other drugs acting on muscles
T48.291 Poisoning by other drugs acting on muscles, accidental (unintentional)
- T48.291A Poisoning by other drugs acting on muscles, accidental (unintentional), initial encounter
- T48.291D Poisoning by other drugs acting on muscles, accidental (unintentional), subsequent encounter
- T48.291S Poisoning by other drugs acting on muscles, accidental (unintentional), sequela
T48.292 Poisoning by other drugs acting on muscles, intentional self-harm
- T48.292A Poisoning by other drugs acting on muscles, intentional self-harm, initial encounter
- T48.292D Poisoning by other drugs acting on muscles, intentional self-harm, subsequent encounter
- T48.292S Poisoning by other drugs acting on muscles, intentional self-harm, sequela
T48.293 Poisoning by other drugs acting on muscles, assault
- T48.293A Poisoning by other drugs acting on muscles, assault, initial encounter
- T48.293D Poisoning by other drugs acting on muscles, assault, subsequent encounter
- T48.293S Poisoning by other drugs acting on muscles, assault, sequela
T48.294 Poisoning by other drugs acting on muscles, undetermined
- T48.294A Poisoning by other drugs acting on muscles, undetermined, initial encounter
- T48.294D Poisoning by other drugs acting on muscles, undetermined, subsequent encounter
- T48.294S Poisoning by other drugs acting on muscles, undetermined, sequela
T48.295 Adverse effect of other drugs acting on muscles
- T48.295A Adverse effect of other drugs acting on muscles, initial encounter
- T48.295D Adverse effect of other drugs acting on muscles, subsequent encounter
- T48.295S Adverse effect of other drugs acting on muscles, sequela
T48.296 Underdosing of other drugs acting on muscles
- T48.296A Underdosing of other drugs acting on muscles, initial encounter
- T48.296D Underdosing of other drugs acting on muscles, subsequent encounter
- T48.296S Underdosing of other drugs acting on muscles, sequela
T48.3 Poisoning by, adverse effect of and underdosing of antitussives
T48.3X Poisoning by, adverse effect of and underdosing of antitussives
T48.3X1 Poisoning by antitussives, accidental (unintentional)
- T48.3X1A Poisoning by antitussives, accidental (unintentional), initial encounter
- T48.3X1D Poisoning by antitussives, accidental (unintentional), subsequent encounter
- T48.3X1S Poisoning by antitussives, accidental (unintentional), sequela
T48.3X2 Poisoning by antitussives, intentional self-harm
- T48.3X2A Poisoning by antitussives, intentional self-harm, initial encounter
- T48.3X2D Poisoning by antitussives, intentional self-harm, subsequent encounter
- T48.3X2S Poisoning by antitussives, intentional self-harm, sequela
T48.3X3 Poisoning by antitussives, assault
- T48.3X3A Poisoning by antitussives, assault, initial encounter
- T48.3X3D Poisoning by antitussives, assault, subsequent encounter
- T48.3X3S Poisoning by antitussives, assault, sequela
T48.3X4 Poisoning by antitussives, undetermined
- T48.3X4A Poisoning by antitussives, undetermined, initial encounter
- T48.3X4D Poisoning by antitussives, undetermined, subsequent encounter
- T48.3X4S Poisoning by antitussives, undetermined, sequela
T48.3X5 Adverse effect of antitussives
- T48.3X5A Adverse effect of antitussives, initial encounter
- T48.3X5D Adverse effect of antitussives, subsequent encounter
- T48.3X5S Adverse effect of antitussives, sequela
T48.3X6 Underdosing of antitussives
- T48.3X6A Underdosing of antitussives, initial encounter
- T48.3X6D Underdosing of antitussives, subsequent encounter
- T48.3X6S Underdosing of antitussives, sequela
T48.4 Poisoning by, adverse effect of and underdosing of expectorants
T48.4X Poisoning by, adverse effect of and underdosing of expectorants
T48.4X1 Poisoning by expectorants, accidental (unintentional)
- T48.4X1A Poisoning by expectorants, accidental (unintentional), initial encounter
- T48.4X1D Poisoning by expectorants, accidental (unintentional), subsequent encounter
- T48.4X1S Poisoning by expectorants, accidental (unintentional), sequela
T48.4X2 Poisoning by expectorants, intentional self-harm
- T48.4X2A Poisoning by expectorants, intentional self-harm, initial encounter
- T48.4X2D Poisoning by expectorants, intentional self-harm, subsequent encounter
- T48.4X2S Poisoning by expectorants, intentional self-harm, sequela
T48.4X3 Poisoning by expectorants, assault
- T48.4X3A Poisoning by expectorants, assault, initial encounter
- T48.4X3D Poisoning by expectorants, assault, subsequent encounter
- T48.4X3S Poisoning by expectorants, assault, sequela
T48.4X4 Poisoning by expectorants, undetermined
- T48.4X4A Poisoning by expectorants, undetermined, initial encounter
- T48.4X4D Poisoning by expectorants, undetermined, subsequent encounter
- T48.4X4S Poisoning by expectorants, undetermined, sequela
T48.4X5 Adverse effect of expectorants
- T48.4X5A Adverse effect of expectorants, initial encounter
- T48.4X5D Adverse effect of expectorants, subsequent encounter
- T48.4X5S Adverse effect of expectorants, sequela
T48.4X6 Underdosing of expectorants
- T48.4X6A Underdosing of expectorants, initial encounter
- T48.4X6D Underdosing of expectorants, subsequent encounter
- T48.4X6S Underdosing of expectorants, sequela
T48.5 Poisoning by, adverse effect of and underdosing of other anti-common-cold drugs
T48.5X Poisoning by, adverse effect of and underdosing of other anti-common-cold drugs
T48.5X1 Poisoning by other anti-common-cold drugs, accidental (unintentional)
- T48.5X1A Poisoning by other anti-common-cold drugs, accidental (unintentional), initial encounter
- T48.5X1D Poisoning by other anti-common-cold drugs, accidental (unintentional), subsequent encounter
- T48.5X1S Poisoning by other anti-common-cold drugs, accidental (unintentional), sequela
T48.5X2 Poisoning by other anti-common-cold drugs, intentional self-harm
- T48.5X2A Poisoning by other anti-common-cold drugs, intentional self-harm, initial encounter
- T48.5X2D Poisoning by other anti-common-cold drugs, intentional self-harm, subsequent encounter
- T48.5X2S Poisoning by other anti-common-cold drugs, intentional self-harm, sequela
T48.5X3 Poisoning by other anti-common-cold drugs, assault
- T48.5X3A Poisoning by other anti-common-cold drugs, assault, initial encounter
- T48.5X3D Poisoning by other anti-common-cold drugs, assault, subsequent encounter
- T48.5X3S Poisoning by other anti-common-cold drugs, assault, sequela
T48.5X4 Poisoning by other anti-common-cold drugs, undetermined
- T48.5X4A Poisoning by other anti-common-cold drugs, undetermined, initial encounter
- T48.5X4D Poisoning by other anti-common-cold drugs, undetermined, subsequent encounter
- T48.5X4S Poisoning by other anti-common-cold drugs, undetermined, sequela
T48.5X5 Adverse effect of other anti-common-cold drugs
- T48.5X5A Adverse effect of other anti-common-cold drugs, initial encounter
- T48.5X5D Adverse effect of other anti-common-cold drugs, subsequent encounter
- T48.5X5S Adverse effect of other anti-common-cold drugs, sequela
T48.5X6 Underdosing of other anti-common-cold drugs
- T48.5X6A Underdosing of other anti-common-cold drugs, initial encounter
- T48.5X6D Underdosing of other anti-common-cold drugs, subsequent encounter
- T48.5X6S Underdosing of other anti-common-cold drugs, sequela
T48.6 Poisoning by, adverse effect of and underdosing of antiasthmatics, not elsewhere classified
T48.6X Poisoning by, adverse effect of and underdosing of antiasthmatics
T48.6X1 Poisoning by antiasthmatics, accidental (unintentional)
- T48.6X1A Poisoning by antiasthmatics, accidental (unintentional), initial encounter
- T48.6X1D Poisoning by antiasthmatics, accidental (unintentional), subsequent encounter
- T48.6X1S Poisoning by antiasthmatics, accidental (unintentional), sequela
T48.6X2 Poisoning by antiasthmatics, intentional self-harm
- T48.6X2A Poisoning by antiasthmatics, intentional self-harm, initial encounter
- T48.6X2D Poisoning by antiasthmatics, intentional self-harm, subsequent encounter
- T48.6X2S Poisoning by antiasthmatics, intentional self-harm, sequela
T48.6X3 Poisoning by antiasthmatics, assault
- T48.6X3A Poisoning by antiasthmatics, assault, initial encounter
- T48.6X3D Poisoning by antiasthmatics, assault, subsequent encounter
- T48.6X3S Poisoning by antiasthmatics, assault, sequela
T48.6X4 Poisoning by antiasthmatics, undetermined
- T48.6X4A Poisoning by antiasthmatics, undetermined, initial encounter
- T48.6X4D Poisoning by antiasthmatics, undetermined, subsequent encounter
- T48.6X4S Poisoning by antiasthmatics, undetermined, sequela
T48.6X5 Adverse effect of antiasthmatics
- T48.6X5A Adverse effect of antiasthmatics, initial encounter
- T48.6X5D Adverse effect of antiasthmatics, subsequent encounter
- T48.6X5S Adverse effect of antiasthmatics, sequela
T48.6X6 Underdosing of antiasthmatics
- T48.6X6A Underdosing of antiasthmatics, initial encounter
- T48.6X6D Underdosing of antiasthmatics, subsequent encounter
- T48.6X6S Underdosing of antiasthmatics, sequela
T48.9 Poisoning by, adverse effect of and underdosing of other and unspecified agents primarily acting on the respiratory system
T48.90 Poisoning by, adverse effect of and underdosing of unspecified agents primarily acting on the respiratory system
T48.901 Poisoning by unspecified agents primarily acting on the respiratory system, accidental (unintentional)
- T48.901A Poisoning by unspecified agents primarily acting on the respiratory system, accidental (unintentional), initial encounter
- T48.901D Poisoning by unspecified agents primarily acting on the respiratory system, accidental (unintentional), subsequent encounter
- T48.901S Poisoning by unspecified agents primarily acting on the respiratory system, accidental (unintentional), sequela
T48.902 Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm
- T48.902A Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, initial encounter
- T48.902D Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter
- T48.902S Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, sequela
T48.903 Poisoning by unspecified agents primarily acting on the respiratory system, assault
- T48.903A Poisoning by unspecified agents primarily acting on the respiratory system, assault, initial encounter
- T48.903D Poisoning by unspecified agents primarily acting on the respiratory system, assault, subsequent encounter
- T48.903S Poisoning by unspecified agents primarily acting on the respiratory system, assault, sequela
T48.904 Poisoning by unspecified agents primarily acting on the respiratory system, undetermined
- T48.904A Poisoning by unspecified agents primarily acting on the respiratory system, undetermined, initial encounter
- T48.904D Poisoning by unspecified agents primarily acting on the respiratory system, undetermined, subsequent encounter
- T48.904S Poisoning by unspecified agents primarily acting on the respiratory system, undetermined, sequela
T48.905 Adverse effect of unspecified agents primarily acting on the respiratory system
- T48.905A Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter
- T48.905D Adverse effect of unspecified agents primarily acting on the respiratory system, subsequent encounter
- T48.905S Adverse effect of unspecified agents primarily acting on the respiratory system, sequela
T48.906 Underdosing of unspecified agents primarily acting on the respiratory system
- T48.906A Underdosing of unspecified agents primarily acting on the respiratory system, initial encounter
- T48.906D Underdosing of unspecified agents primarily acting on the respiratory system, subsequent encounter
- T48.906S Underdosing of unspecified agents primarily acting on the respiratory system, sequela
T48.99 Poisoning by, adverse effect of and underdosing of other agents primarily acting on the respiratory system
T48.991 Poisoning by other agents primarily acting on the respiratory system, accidental (unintentional)
- T48.991A Poisoning by other agents primarily acting on the respiratory system, accidental (unintentional), initial encounter
- T48.991D Poisoning by other agents primarily acting on the respiratory system, accidental (unintentional), subsequent encounter
- T48.991S Poisoning by other agents primarily acting on the respiratory system, accidental (unintentional), sequela
T48.992 Poisoning by other agents primarily acting on the respiratory system, intentional self-harm
- T48.992A Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, initial encounter
- T48.992D Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter
- T48.992S Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, sequela
T48.993 Poisoning by other agents primarily acting on the respiratory system, assault
- T48.993A Poisoning by other agents primarily acting on the respiratory system, assault, initial encounter
- T48.993D Poisoning by other agents primarily acting on the respiratory system, assault, subsequent encounter
- T48.993S Poisoning by other agents primarily acting on the respiratory system, assault, sequela
T48.994 Poisoning by other agents primarily acting on the respiratory system, undetermined
- T48.994A Poisoning by other agents primarily acting on the respiratory system, undetermined, initial encounter
- T48.994D Poisoning by other agents primarily acting on the respiratory system, undetermined, subsequent encounter
- T48.994S Poisoning by other agents primarily acting on the respiratory system, undetermined, sequela
T48.995 Adverse effect of other agents primarily acting on the respiratory system
- T48.995A Adverse effect of other agents primarily acting on the respiratory system, initial encounter
- T48.995D Adverse effect of other agents primarily acting on the respiratory system, subsequent encounter
- T48.995S Adverse effect of other agents primarily acting on the respiratory system, sequela
T48.996 Underdosing of other agents primarily acting on the respiratory system
- T48.996A Underdosing of other agents primarily acting on the respiratory system, initial encounter
- T48.996D Underdosing of other agents primarily acting on the respiratory system, subsequent encounter
- T48.996S Underdosing of other agents primarily acting on the respiratory system, sequela
Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system (T48)